Prévisions
L'objectif de cours moyen des analystes est de 15,47 € (+343,27 %). La médiane est de 18,20 € (+421,49 %).
| Acheter |
8 |
| Conserver |
2 |
| Vendre |
0 |
Discussions dans la communauté
Il n'y a pas encore de discussion sur cet actif.
Lancer une discussionActualités Accéder au fil d'actualités
Nuvation Bio reports strong launch of IBTROZI and positive Safusidenib data
At the Cantor Fitzgerald Healthcare Conference, Nuvation Bio said IBTROZI reached roughly 20% of the theoretical ROS1 market in its first year and uptake in first-line therapy continues to grow. The company holds $700 million in cash and considers itself well positioned financially to fund commercialization and its pipeline. Safusidenib showed a 79% non‑progression rate and a 52% response rate at 3 years, and multiple studies are planned through 2029. Management forecasts a peak sales potential for IBTROZI of $4–5 billion at full market penetration, while warning of development risks and emphasizing disciplined capital deployment. » Plus sur de.investing.com
Nuvation Bio receives FDA fast-track for safusidenib and Cantor-Fitzgerald starts coverage with 12 USD target
The FDA granted safusidenib fast-track status for the treatment of IDH1‑mutated gliomas based on phase 2 data (confirmed objective response rate 51.9%, median progression‑free survival not yet reached, 36‑month PFS 79.1%). The designation enables more intensive interaction with the agency and a possible rolling review, reducing regulatory risk while the phase 3 SIGMA study continues to enroll. Cantor Fitzgerald initiated coverage with an “Overweight” rating and set a price target of 12 USD, with revenue forecasts of roughly 965 million USD for IBTROZI and about 1.9 billion USD for safusidenib. The news pushed the stock higher intraday (rise to 7.02 USD). » Plus sur de.investing.com
Nuvation Bio receives FDA fast-track for safusidenib in IDH1 gliomas
The FDA has granted fast-track designation to safusidenib, an oral investigational candidate from Nuvation Bio for the treatment of IDH1‑mutant gliomas. The decision is based on phase‑2 data (J201) showing a confirmed objective response rate of 51.9% and a 36‑month progression‑free survival of 79.1%; median PFS has not yet been reached. Nuvation is currently recruiting for the registrational phase‑3 SIGMA trial, which will evaluate safusidenib as maintenance therapy versus placebo after standard treatment in IDH1‑mutant astrocytomas with high‑risk features (about 300 patients). Safusidenib is a selective inhibitor of mutant IDH1 designed to penetrate the blood–brain barrier; no new long‑term safety signals have been reported. » Plus sur de.investing.com
Nuvation Bio receives Overweight from JPMorgan after robust second quarter
Nuvation Bio reports a solid second quarter and cash of $661 million. JPMorgan initiated coverage with an "Overweight" rating and a $13 price target, supported by expected first-line uptake. The bank sees additional revenue potential in prevalence-driven gene sequencing and in the pipeline around Safusidenib; the company remains focused on targeted cancer therapies and has a strengthened capital base. » Plus sur finanzen.net
Nuvation Bio reports Q2 revenue growth for IBTROZI and expands safusidenib trials
Nuvation Bio posted Q2 total revenue of $31.7 million with U.S. IBTROZI product sales of $23.2 million, a 25% sequential increase as use shifts toward first-line ROS1 patients. Management highlighted stronger first-line uptake and longer treatment durations, supported by favorable TRUST-I and patient-reported outcomes. The company expanded safusidenib development with a Phase III trial in newly diagnosed Grade 2 IDH1-mutant glioma and a Phase II study for post-vorasidenib patients, citing durable Phase II results. Nuvation ended June with $661 million in cash and securities and raised about $279.1 million via convertible notes, which management says supports operations through profitability and the anticipated safusidenib launch. » Plus sur finance.yahoo.com
Données financières
Au dernier trimestre, Nuvation Bio Inc Ordinary Shares - Class A a réalisé un chiffre d'affaires de 39,68 M € et un bénéfice net de -36,99 M €
| (EUR) | septembre 2026 | YoY |
|---|---|---|
| Chiffre d'affaires | 39,68 M | 254,97 % |
| Bénéfice brut | 29,15 M | 250,14 % |
| Bénéfice net | -36,99 M | 22,19 % |
| EBITDA | -31,08 M | 33,39 % |
Données fondamentales
| Indicateur | Valeur |
|---|---|
Capitalisation boursière | 1,21 Md € |
Nombre d'actions | 352,02 M |
Plus haut/bas sur 52 semaines | 8,87 € - 3,43 € |
| Dividendes | Non |
Bêta | 1,73 |
Ratio P/E | -9,58 |
Ratio PEG | -0,20 |
Ratio P/B | 5,83 |
Ratio P/S | 6,60 |
Profil de l'entreprise
Nuvation Bio Inc., une société biopharmaceutique au stade clinique, se concentre sur le développement de candidats thérapeutiques en oncologie. Le principal candidat produit de la société est le NUV-422, un inhibiteur à petites molécules ciblant les kinases dépendantes des cyclines (CDK) 2, CDK4 et CDK6. Elle développe également le NUV-868, un inhibiteur oral sélectif à petites molécules de BET qui régule sur le plan épigénétique des protéines contrôlant la croissance et la différenciation tumorales ; le NUV-569, un inhibiteur oral sélectif à petites molécules différencié de la kinase Wee1 pour la réparation des dommages à l'ADN ; le NUV-1182, un inhibiteur des récepteurs de l'adénosine ; ainsi qu'une plateforme de conjugués médicament-médicament (DDC) qui vise à associer un inhibiteur de la poly(ADP-ribose) polymérase (PARP) aux charges anticancéreuses de médicaments existants, ainsi qu'un inhibiteur de PARP destiné à traiter les cancers du sein ER+ et de l'ovaire. La société était auparavant connue sous le nom de RePharmation Inc. et a changé sa dénomination en Nuvation Bio Inc. en avril 2019. Nuvation Bio Inc. a été fondée en 2018 et son siège social se trouve à New York, New York.
| Nom | Nuvation Bio Inc Ordinary Shares - Class A |
| PDG | David T. Hung |
| Siège social | New York City,
ny États-Unis |
| Site web | |
| Secteur | Matériaux |
| Industrie | Produits chimiques |
| Introduction en bourse | 26/08/2020 |
| Employés | 310 |
Symboles boursiers
| Bourse | Symbole |
|---|---|
NYSE | NUVB |